Itamol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Itamol

Property Description
Active ingredient Acetaminophen (INN)
Common Form Oral Tablets, Suspension
Pharmacological class Analgesic, Antipyretic
General Use Symptomatic relief of pain and fever
Origin Synthetic Compound

Itamol is a widely recognized, over-the-counter (OTC) medicine categorized primarily as an analgesic (pain reliever) and an antipyretic (fever reducer). Its active substance is known internationally as Acetaminophen, the generic name used for international classification.

As part of the anilide pharmacological class, Itamol is one of the most common medications globally for managing mild-to-moderate discomfort. It has a clinically recognized efficacy in providing temporary relief.


What is Itamol Made Of and Where Does it Come From?

The active compound in Itamol is entirely synthetic, created through controlled chemical synthesis in a laboratory setting. This deliberate manufacturing process ensures that the finished drug product maintains high chemical purity and potency. Pharmacologically, it is recognized as a compound distinct from traditional non-steroidal anti-inflammatory drugs (NSAIDs), emphasizing its focused role in pain and fever management.

Itamol is often differentiated in the market by its smooth, film-coated tablet form, which is designed for easier swallowing compared to uncoated alternatives. This synthetic origin allows for consistent quality and mass production, contributing to its global availability.


General Use: What Conditions is Itamol For?

The fundamental purpose of Itamol is to provide symptomatic relief for acute discomfort and elevated body temperature. It is widely used for common complaints such as tension headaches, muscle aches, and fever associated with common illnesses. The drug's therapeutic role is associated with its effect on central pain pathways.

It is essential to remember that Itamol alleviates the symptom—pain or fever—but does not treat the underlying disease causing the symptom. Its role is supportive, intended for temporary use until the condition naturally resolves or a primary treatment is initiated.

Regulatory References

  1. MedlinePlus Summary

What side effects are possible with Itamol?

Possible Side Effects and Safety Information

The safety profile of Itamol (Acetaminophen) is formally documented by regulatory agencies, with risks primarily categorized by system-organ class and frequency. The most critical safety constraint relates to hepatotoxicity (liver damage), which is strongly associated with exceeding the maximum recommended daily intake, either through acute overdose or prolonged high-dose use. Regulatory documents specify that severe liver failure and hepatic necrosis are serious adverse reactions, often linked to this misuse.

Adverse reactions are generally classified as rare or very rare. Reactions involving the Blood and Lymphatic System, such as Agranulocytosis and Thrombocytopenia, fall into the rare category. Severe, life-threatening events, including Anaphylactic shock and severe skin conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are classified as very rare.

Adverse Reaction Scope (Regulatory Classification) Key Examples
Hepatobiliary Disorders (Serious) Liver failure, Hepatic necrosis
Skin & Subcutaneous Tissue Disorders Rash, Urticaria, SJS, TEN
Blood & Lymphatic System Disorders (Rare) Agranulocytosis, Thrombocytopenia

Official labeling defines specific safety considerations. Individuals with severe active hepatic disease are generally subject to contraindications. Caution is also advised in patients with severe renal impairment and those with a history of chronic alcohol consumption. The paramount safety restriction requires individuals to avoid combining Itamol with any other medicine containing acetaminophen to prevent severe, life-threatening toxicity.

Overdose and Emergency Response

Overdose with Itamol (Acetaminophen) is officially documented by regulatory authorities as a time-critical event primarily associated with severe hepatotoxicity, or liver damage. Initial signs of overdose are often nonspecific and may include nausea, vomiting, anorexia, and diaphoresis (excessive sweating).

Critically, these early manifestations may resolve, creating a false sense of security before the potentially life-threatening liver injury becomes clinically apparent. According to regulatory documents, the delayed severe outcomes may include fulminant hepatic necrosis, liver failure, metabolic acidosis, hypoglycemia, and progression to hepatic encephalopathy, coma, and death. The official labeling notes that individuals with pre-existing hepatic impairment or chronic alcohol use are at an increased risk for severe toxicity.

Urgent medical evaluation is mandated in all suspected cases of overdose. It is an official requirement to seek immediate medical attention and contact a poison control center immediately, even if no symptoms are observed. This necessity is driven by the need for timely management, as the specific antidote, N-acetylcysteine, must be administered early for maximum efficacy. Furthermore, regulatory guidelines state that intensive medical monitoring and laboratory testing, including plasma acetaminophen concentrations and liver function tests, are required in a hospital setting.

Therapeutic Uses of Itamol

What Itamol Treats: Main Uses and Benefits

Itamol is generally used to help with symptomatic support for mild-to-moderate pain and to reduce fever. This medicine is applicable within clinical settings that involve acute or disruptive symptom patterns, providing support that helps ease the overall symptom burden. It is commonly used for managing symptoms related to physical discomfort such as tension headaches, backache, muscular aches, toothache, and cyclical pain like menstrual cramps.

Itamol is used for managing symptoms that interfere with daily comfort, including the systemic imbalance of fever often associated with the common cold and flu. This supportive role assists with maintaining functional stability when symptoms interfere with routine activities. It is relevant when supportive symptom management is appropriate across patient groups, including adults, children, and older adults.


Quick Fact: Relevant for Symptoms of Mild-to-Moderate Discomfort

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Itamol

Official regulatory documents define the eligibility for Itamol (Acetaminophen) based on absolute contraindications, patient age, and pre-existing health status.

Absolute Contraindications

Itamol must not be used by patients with a known hypersensitivity (allergy) to Acetaminophen or any component of the formulation. Use is also strictly contraindicated for individuals with severe hepatic impairment or active liver disease. Due to the critical risk of accidental overdose, Itamol is prohibited for anyone concurrently taking any other medicine that contains acetaminophen.

Conditional and Restricted Use

Population Group Regulatory Status
Chronic Alcohol Abusers Use requires caution and may be restricted.
Severe Renal Impairment Conditional use; may require supervision.
Mild to Moderate Liver Disease Conditional use; requires caution.

Age and Physiological Constraints

Eligibility is established for adults and adolescents. For over-the-counter (OTC) use, Itamol is not recommended for children under 2 years unless directed by a physician. During pregnancy, use is permitted when clinically necessary, with an official regulatory emphasis on utilizing the lowest effective dose for the shortest duration. Use while breastfeeding is generally deemed acceptable by regulatory authorities.

What should I know about interactions with other medicines?

Itamol Interactions with other medicines and products

The interaction profile of Itamol (acetaminophen) is defined by pharmacokinetic changes that alter its clearance and pharmacodynamic outcomes that modify specific toxicity risks, all documented in regulatory labeling.


Documented Interaction Constraints

Interaction Type Interacting Substance(s) Official Regulatory Statement
Prohibited Combination Other Acetaminophen Products Co-administration with any other acetaminophen-containing product (prescription or non-prescription) is strictly prohibited to prevent the risk of severe hepatotoxicity.
Substance Restriction Alcohol (Ethanol) Chronic, excessive consumption (three or more drinks daily) is documented to increase the risk of severe liver damage when using Itamol.

Exposure and Effect Alterations

  • Anticoagulants: Prolonged regular use of Itamol may enhance the effect of Warfarin, increasing the risk of bleeding. The label advises increased monitoring of the patient's coagulation status.
  • Enzyme Inducers: Co-use with agents like Carbamazepine or Rifampicin can accelerate the formation of the toxic metabolite, escalating hepatotoxicity risk in overdose.
  • Absorption Rate: Agents like Metoclopramide and Domperidone are documented to increase the rate of Itamol's absorption.
  • Clearance: Probenecid officially reduces Itamol's clearance, which increases its plasma concentration and may require attention to dose.
  • Specific Toxicity Risk: Concurrent, chronic use with Zidovudine is associated with an officially documented increased risk of neutropenia.

Timing Separation Rules

  • Cholestyramine: To mitigate the documented reduction in Itamol's absorption caused by this agent, Itamol must be administered at least one hour before or four to six hours after Cholestyramine.

Mechanism of Action

Central Inhibition of Prostaglandin Synthesis

Itamol exerts its primary action by functioning as an inhibitor of specific Cyclooxygenase (COX) enzymes, including COX-2 and a possible COX-3 variant, predominantly within the Central Nervous System (CNS). This inhibition restricts the synthesis of key pro-inflammatory and signaling mediators, notably Prostaglandin E2 (PGE2). The reduction of PGE2 activity is integral to modulating both the thermoregulatory set point and nociceptive signal transmission in the CNS.


Pathway Modulation and Physiological Consequence

The mechanism extends to include modulation of complex neural signaling pathways, specifically involving serotonergic (5-HT) and endocannabinoid systems. This modulation reinforces the activity of descending inhibitory pathways, which influence the transmission of nociceptive signals toward the cerebrum. The resulting physiological cascade includes the alteration of the hypothalamic thermoregulatory set point and a simultaneous reduction in afferent nociceptive signaling, which collectively define the drug's fundamental central effect profile.

Dosage and Administration Information

Itamol (Acetaminophen) administration follows standard protocols across its three official routes: Oral (tablets, suspension), Rectal (suppositories), and Intravenous (IV) infusion, which is primarily restricted to hospital settings. The general principle of usage is governed by limits on frequency and total daily exposure.

For adults weighing 50 kg or more, the typical single oral dose ranges from 650 mg to 1,000 mg, with doses taken every four to six hours as needed. The absolute maximum total daily dose from all sources, including combination products containing acetaminophen, must not exceed 4,000 mg (4 g) in any 24-hour period. Oral forms may be taken with or without food, as instructions indicate that a fasted state may only accelerate the onset of action, not the overall effect.

Administration patterns are designed for short-term, acute symptomatic support. Self-treatment should be limited to a maximum of 10 days for pain and 3 days for fever, unless directed otherwise. Dosing must be specifically adjusted for certain patient populations; for instance, pediatric administration is strictly weight-based (12.5–15 mg/kg per dose), and individuals with severe hepatic or renal impairment require a reduction in the total daily dose or an extension of the minimum dosing interval to 6 or 8 hours. This ensures the medicine is used within established therapeutic limits.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of [Drug Name] Studies

Research has explored whether joint health and mobility are affected in animal models. Studies were conducted to evaluate whether this combination of compounds could affect inflammation and joint discomfort; findings were mixed regarding a sustained effect.

Research has also focused on the individual components, [Compound X] and [Compound Y], to understand their potential role in joint health research.


Research on [Compound X]

Research has explored the use of [Compound X] for the early management of osteoarthritis. One randomized controlled trial (RCT) examined 150 participants over 12 weeks.

  • Study Design: The trial design compared [Compound X] (at a 100 mg daily regimen) against a placebo.
  • Key Findings: The RCT indicated that participants receiving [Compound X] reported lower average scores on the WOMAC pain subscale at 12 weeks compared to the placebo group.
  • Study Findings on Safety: The trial reported no serious adverse events; participants in the trial noted mild gastrointestinal discomfort.

Clinical studies have not yet fully established the safety profile for all patient populations and treatment suitability.


Research on [Compound Y]

Studies examined whether the ingredient could impact pain associated with physical activity. A meta-analysis published in 2022 reviewed 8 studies involving over 800 subjects.

  • Study Design: The analysis pooled data from studies examining the effect of [Compound Y] on joint discomfort after exercise. The study protocols involved various regimens ranging from 50 mg to 200 mg daily.
  • Key Findings: Five of the eight included studies reported that participants receiving [Compound Y] had a statistically smaller increase in reported pain after physical activity compared to control groups. Three studies reported no significant difference.
  • Dosage Evaluation: One study protocol examined a regimen of one capsule daily. The findings did not detail the concept of 'optimal results'.

Combination Therapy Studies

The combination of [Compound X] and [Compound Y] has been the subject of two independent, non-randomized pilot studies.

  • Study Scope: The pilot studies included a total of 55 subjects with mild to moderate joint discomfort.
  • Observed Effects: Initial findings show the treatment was evaluated for its potential to affect physical function, particularly when studied in combination with physical therapy. The findings that received the most attention were those observed when administration was initiated within 6 months of symptom onset.
  • Conclusion: This treatment is one area of active research for managing degenerative joint issues. Further, larger-scale RCTs are required to confirm any potential finding or to establish clinical suitability.

Key Studies & References

  1. The Role of Physical Exercise in Chronic Musculoskeletal Pain: Best Medicine—A Narrative Review (Supporting reference for Compound Y effect on physical activity/pain)

Frequently Asked Questions (FAQ)

Common questions about Itamol (FAQ)


Q: How quickly should I expect to feel the effect of Itamol?

A: Official information indicates that Itamol, when taken orally, generally begins to relieve pain within 30 to 60 minutes. Taking the medicine in a fasted state may slightly accelerate this initial onset of action, though it does not change the medicine’s overall effect.


Q: Can Itamol be taken with certain types of food?

A: Itamol is described in official product information as being suitable to be taken with or without food. Regulatory information confirms that while consuming it on an empty stomach might quicken the onset, taking it with food does not significantly affect its overall effectiveness as a pain or fever reducer.


Q: Does taking Itamol affect the results of any lab tests?

A: Regulatory documents mention that regular or prolonged use of Itamol may interfere with the monitoring of coagulation status for individuals taking anticoagulant medicines. Regulatory labeling indicates that a healthcare professional should be aware of all medications being taken prior to lab work.


Q: Is Itamol used only for short-term problems?

A: For self-treatment without medical supervision, official guidelines limit use to a maximum of 10 days for pain and 3 days for fever. If symptomatic relief is required beyond these short periods, this would be a matter for professional medical review.


Q: Can Itamol be taken by people with diabetes?

A: Diabetes is not listed as a specific condition that contraindicates the use of Itamol or requires an automatic dose change in official product information. However, specific liquid or chewable formulations may contain excipients (inactive ingredients) like sugars or phenylalanine, and individuals with dietary concerns may wish to review the product's official excipient list for details on inactive ingredients.


Q: Can Itamol be crushed or split?

A: Official administration instructions typically describe that tablets should be swallowed whole. Crushing or splitting tablets is generally discouraged unless the product is specifically labeled as a chewable or orally disintegrating form, especially to avoid disrupting the intended release of medication.


Q: Can Itamol affect my ability to drive or operate machinery?

A: Official regulatory documents for single-ingredient Itamol generally state that the medicine is not known to impair the ability to drive or operate machinery. Warnings related to combination products containing sedating ingredients are documented separately in their respective regulatory information.


Q: Is Itamol the same as acetaminophen or ibuprofen?

A: The active ingredient in Itamol is acetaminophen, which is described in official sources as an analgesic (pain reliever) and antipyretic (fever reducer). It is structurally and pharmacologically distinct from ibuprofen, which belongs to a different class of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs).


Q: What is the main difference between Itamol and a typical pain reliever?

A: Official documents highlight that Itamol's action is predominantly in the Central Nervous System (the brain and spinal cord). This mechanism is noted as distinct from the peripheral mechanisms of NSAID pain relievers. Unlike NSAIDs, Itamol does not typically cause the same level of stomach irritation or affect blood clotting.


Q: Does Itamol cause fatigue or drowsiness?

A: While drowsiness is listed as a recognized adverse reaction in some official safety documents, it is not consistently reported as a common side effect. Official information does not consistently identify fatigue as a common side effect of the standard single-ingredient product.


Q: Is Itamol available over the counter in some countries?

A: Yes, Itamol (acetaminophen) is widely available as an Over-The-Counter (OTC) medicine in many countries globally. Regulatory agencies define specific conditions for OTC availability, including controls on package size.


Q: Does Itamol have any effect on blood pressure?

A: Official regulatory documents typically do not list effects on blood pressure among the common or expected side effects of standard, single-ingredient Itamol. Cardiovascular effects are generally not a primary safety concern for this medicine.


Q: Can people who are lactose intolerant take Itamol?

A: The suitability of Itamol for individuals with lactose intolerance depends on the inactive ingredients (excipients) used in the specific formulation. Individuals with intolerances are often advised to review the product's official excipient list for details on inactive ingredients.


Q: Are there different strengths or forms of Itamol?

A: Yes, regulatory documents describe that Itamol is manufactured in various pharmaceutical forms and strengths. These include different concentrations of oral tablets, liquid suspensions, rectal suppositories, and solutions for use in hospital settings.


Q: What research exists about Itamol's use in children?

A: The use of Itamol in children is supported by extensive research that allows regulatory agencies to provide specific, weight-based dosing guidance for pediatric administration. However, it is not recommended for children under 2 years of age for OTC use without professional guidance.


Q: Does the time of day matter when taking Itamol?

A: The most critical factor defined in official administration instructions is adhering to the correct frequency interval (e.g., every four to six hours) and ensuring the maximum total daily dose is not exceeded, rather than specifying a particular time of day for administration.


Q: Is Itamol metabolized differently in certain ethnic groups?

A: Regulatory information addresses differences in how the drug is processed primarily in relation to pre-existing conditions like severe liver or kidney impairment, or certain rare genetic conditions. Official guidance does not provide specific dose adjustments based on ethnic group.


Q: Is it normal to feel a mild headache when starting Itamol?

A: Headache is listed as a recognized adverse reaction in some official safety documents. Although it is not consistently categorized as a very common effect, it is a known possibility reported in patient populations.


Q: Is Itamol physically addictive or habit-forming?

A: Itamol (acetaminophen) is not classified as an opioid or controlled substance. Official information does not associate this medicine with physical addiction or habit-forming potential.


Q: What should I do if a rash appears while taking Itamol?

A: Regulatory labeling states that the appearance of a rash, blistering, or skin reddening is a sign of a potentially serious reaction. If a skin reaction occurs, the product should be discontinued and medical attention sought.


Q: Does Itamol interact with common vaccines?

A: General drug interaction databases from regulatory sources typically indicate that there are no known major interactions between Itamol and common vaccines.


Q: Is there a maximum time frame for safely using Itamol?

A: The primary safety measure defined by regulatory agencies is the absolute maximum total daily dosage (typically 4,000 mg in 24 hours for adults). This, combined with the short-term use limitations for self-treatment (10 days for pain, 3 days for fever), defines the regulatory constraints on its use.


Q: Do older adults typically need a different dose of Itamol?

A: Standard dosing for Itamol does not require a general dose reduction for otherwise healthy older adults based on age alone. However, dose adjustments are explicitly required for patients with severe kidney or liver impairment, which are conditions that may require dose attention in any population.


Q: Can Itamol be used by people with specific genetic conditions?

A: Regulatory information notes that caution may be necessary for people with certain genetic conditions, such as G6PD deficiency. When used in these cases, it is often done under supervision and at standard therapeutic doses.


Q: What happens if I take Itamol too close to another medicine?

A: Official regulatory documents specifically note that a timing separation rule is necessary for one medicine, Cholestyramine. Itamol must be administered either one hour before or four to six hours after Cholestyramine to ensure proper absorption.


Q: Why are people often confused about the active ingredient in Itamol?

A: This confusion arises because the same active ingredient is known by two different international names: Acetaminophen (used in the US and Japan) and Paracetamol (used in the UK, Europe, and Australia). Both names refer to the identical chemical compound.

How should Itamol be stored and disposed of?

How to Store and Dispose of Itamol?

Itamol (acetaminophen) must be stored under specific regulatory conditions to maintain stability. The medicine must be kept at Controlled Room Temperature, typically 20 mathrmC to 25 mathrmC (68 mathrmF to 77 mathrmF). It must be protected from excessive moisture and excessive heat (above 40 mathrmC). Liquid forms should also be protected from freezing.

The container must be kept tightly closed and in its original packaging. A mandatory label requirement is to store the product out of the sight and reach of children.

Disposal should follow official guidelines. Unused or expired medication should be taken to an approved drug take-back program. If this is not possible, the product should be mixed with an undesirable substance (e.g., dirt) and sealed in a bag before being placed in household trash; it must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Itamol found in:

A-Z Index: